Breast cancer: further evidence supporting the clinical use of circulating biomarkers
Monitoring circulating tumor DNA (ctDNA) to detect ESR1 resistance mutations allows early therapeutic adaptation with Camizestrant, leading to significant improvements in progression‑free survival among hormone‑dependent metastatic breast cancer patients.
The phase 3 SERENA‑6 trial, conducted in almost 3,000 women with hormone‑dependent metastatic breast cancer, showed that early detection of ESR1 mutations by circulating tumour DNA and subsequent switch to Camizestrant improves median progression‑free survival by 7.6 months and sustains benefit over longer follow‑up (PFS2 improvement of 6.6 months). The study supports ctDNA‑guided adaptive therapy as a new paradigm in endocrine‑resistant breast cancer management.
Early identification of resistance mutations enables timely therapeutic changes before clinical progression, improving survival outcomes and maintaining treatment tolerability, thereby offering a more precise and patient‑centric approach to metastatic breast cancer care.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC